Last A$0.53 AUD
Change Today +0.01 / 1.92%
Volume 135.4K
As of 10:51 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

starpharma holdings ltd (SPL) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/23/14 - A$0.99
52 Week Low
12/16/14 - A$0.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

starpharma holdings ltd (SPL) Related Businessweek News

No Related Businessweek News Found

starpharma holdings ltd (SPL) Details

Starpharma Holdings Limited researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and other applications primarily in Australia. The company focuses on the development of VivaGel, a microbicidal agent in Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for prevention of sexual transmitted infections. It also develops dendrimer-enhanced, or DEP versions of existing drugs, including DEP docetaxel in Phase I clinical trial for breast, prostate, lung, and ovarian tumor; and agrochemicals. Starpharma Holdings Limited was founded in 1996 and is headquartered in Melbourne, Australia.

Founded in 1996

starpharma holdings ltd (SPL) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: A$603.6K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$222.6K
Vice President of Development & Regulatory Af...
Total Annual Compensation: A$237.2K
Vice President of Business Development
Total Annual Compensation: A$237.1K
Vice President of Research
Total Annual Compensation: A$236.8K
Compensation as of Fiscal Year 2014.

starpharma holdings ltd (SPL) Key Developments

Starpharma Holdings Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Starpharma Holdings Limited reported consolidated earnings results for the half year ended December 31, 2014. For the period, the company reported revenue from continuing operations of AUD 730,000 compared to AUD 718,000 a year ago. Loss before income tax was AUD 8,538,000 compared to AUD 5,574,000 a year ago. Loss from continuing operations attributable to ordinary equity holders of the company was AUD 8,538,000 or AUD 2.83 per basic and diluted share compared to AUD 5,574,000 or AUD 1.96 per basic and diluted share a year ago. Net cash out flows from operating activities was AUD 5,125,000 compared to AUD 5,999,000 a year ago. Payments for property, plant and equipment was AUD 433,000 compared to AUD 156,000 a year ago.

Starpharma Holdings Limited to Report First Half, 2015 Results on Feb 13, 2015

Starpharma Holdings Limited announced that they will report first half, 2015 results on Feb 13, 2015

Starpharma Holdings Limited Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 01:45 PM

Starpharma Holdings Limited Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 01:45 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Jacinth K. Fairley, Chief Executive Officer and Executive Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPL:AU A$0.53 AUD +0.01

SPL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SPL.
View Industry Companies

Industry Analysis


Industry Average

Valuation SPL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 119.5x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 95.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STARPHARMA HOLDINGS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at